Form 4: Allovir CFO Vikas Sinha Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Vikas Sinha, CFO of Allovir, sold 3,159 shares of common stock on August 19, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On August 19, 2024, Vikas Sinha, the President and CFO of Allovir, sold 3,159 shares of Allovir common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at a weighted average price of $0.7595, with individual transactions ranging from $0.7373 to $0.7736.
- Following the transaction, Sinha directly owns 1,153,584 shares of Allovir common stock.
- Sinha may also be deemed to have shared voting and investment power over 16,674,766 shares held by ElevateBio LLC, where he serves as a director and CFO, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations are a routine part of equity compensation for executives. The sale itself is unlikely to have a significant impact on the stock price, but it does provide insight into management's equity holdings and compensation structure.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are common across the biotechnology industry.
- Comparable companies such as Gilead Sciences, Amgen, and Biogen also see similar transactions by their executives.
- The size of the sale is relatively small compared to the overall holdings of the reporting person.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the stated reason (tax obligations) mitigates this concern.
- The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be negligible.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of stock sale transaction |
| 08/20/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.